Estónsko - estónčina - Ravimiamet

chanelle pharmaceuticals manufacturing limited - prasikvanteel+febanteel+püranteel - tablett - 175mg+525mg+175mg 208tk; 175mg+525mg+175mg 80tk; 175mg+525mg+175mg 96tk; 175mg+525mg+175mg 250tk; 175mg+525mg+175mg 48tk; 175mg+525mg+175mg 120tk; 175mg+525mg+175mg 180tk; 175mg+525mg+175mg 52tk; 175mg+525mg+175mg 204tk; 175mg+525mg+175mg 24tk; 175mg+525mg+175mg 140tk; 175mg+525mg+175mg 16tk; 175mg+525mg+175mg 2tk; 175mg+525mg+175mg 300tk; 175mg+525mg+175mg 206tk; 175mg+525mg+175mg 56tk; 175mg+525mg+175mg 112tk; 175mg+525mg+175mg 98tk; 175mg+525mg+175mg 70tk; 175mg+525mg+175mg 10tk; 175mg+525mg+175mg 108tk; 175mg+525mg+175mg 8tk; 175mg+525mg+175mg 100tk; 175mg+525mg+175mg 84tk; 175mg+525mg+175mg 72tk; 175mg+525mg+175mg 60tk; 175mg+525mg+175mg 30tk; 175mg+525mg+175mg 32tk; 175mg+525mg+175mg 12tk; 175mg+525mg+175mg 4tk; 175mg+525mg+175mg 76tk; 175mg+525mg+175mg 500tk; 175mg+525mg+175mg 92tk; 175mg+525mg+175mg 106tk; 175mg+525mg+175mg 20tk; 175mg+525mg+175mg 18tk; 175mg+525mg+175mg 50tk; 175mg+525mg+175mg 14tk; 175mg+525mg+175mg 6tk; 175mg+525mg+175mg 1000tk; 175mg+525mg+175mg 40tk

Estónsko - estónčina - Ravimiamet

chanelle pharmaceuticals manufacturing limited - prasikvanteel+febanteel+püranteel - tablett - 175mg+525mg+175mg 206tk; 175mg+525mg+175mg 52tk; 175mg+525mg+175mg 72tk; 175mg+525mg+175mg 208tk; 175mg+525mg+175mg 8tk; 175mg+525mg+175mg 70tk; 175mg+525mg+175mg 98tk; 175mg+525mg+175mg 76tk; 175mg+525mg+175mg 1000tk; 175mg+525mg+175mg 108tk; 175mg+525mg+175mg 16tk; 175mg+525mg+175mg 50tk; 175mg+525mg+175mg 42tk; 175mg+525mg+175mg 100tk; 175mg+525mg+175mg 104tk; 175mg+525mg+175mg 120tk; 175mg+525mg+175mg 180tk; 175mg+525mg+175mg 30tk; 175mg+525mg+175mg 36tk; 175mg+525mg+175mg 200tk; 175mg+525mg+175mg 80tk; 175mg+525mg+175mg 92tk; 175mg+525mg+175mg 60tk; 175mg+525mg+175mg 116tk; 175mg+525mg+175mg 5tk; 175mg+525mg+175mg 6tk; 175mg+525mg+175mg 280tk; 175mg+525mg+175mg 18tk; 175mg+525mg+175mg 112tk; 175mg+525mg+175mg 250tk; 175mg+525mg+175mg 84tk; 175mg+525mg+175mg 204tk; 175mg+525mg+175mg 96tk; 175mg+525mg+175mg 150tk; 175mg+525mg+175mg 12tk; 175mg+525mg+175mg 44tk; 175mg+525mg+175mg 64tk; 175mg+525mg+175mg 56tk; 175mg+525mg+175mg 500tk; 175mg+525mg+175mg 140tk; 175mg+525mg+175mg 300tk; 175mg+525mg+175mg 48tk;

Estónsko - estónčina - Ravimiamet

chanelle pharmaceuticals manufacturing limited - prasikvanteel+febanteel+püranteel - tablett - 50mg+150mg+50mg 32tk; 50mg+150mg+50mg 200tk; 50mg+150mg+50mg 60tk; 50mg+150mg+50mg 2tk; 50mg+150mg+50mg 150tk; 50mg+150mg+50mg 280tk; 50mg+150mg+50mg 16tk; 50mg+150mg+50mg 52tk; 50mg+150mg+50mg 120tk; 50mg+150mg+50mg 300tk; 50mg+150mg+50mg 70tk; 50mg+150mg+50mg 1000tk; 50mg+150mg+50mg 20tk; 50mg+150mg+50mg 28tk; 50mg+150mg+50mg 80tk; 50mg+150mg+50mg 6tk; 50mg+150mg+50mg 180tk; 50mg+150mg+50mg 12tk; 50mg+150mg+50mg 42tk; 50mg+150mg+50mg 56tk; 50mg+150mg+50mg 48tk; 50mg+150mg+50mg 106tk; 50mg+150mg+50mg 8tk; 50mg+150mg+50mg 30tk; 50mg+150mg+50mg 84tk; 50mg+150mg+50mg 14tk; 50mg+150mg+50mg 100tk; 50mg+150mg+50mg 500tk; 50mg+150mg+50mg 40tk; 50mg+150mg+50mg 204tk; 50mg+150mg+50mg 10tk; 50mg+150mg+50mg 24tk; 50mg+150mg+50mg 250tk; 50mg+150mg+50mg 18tk; 50mg+150mg+50mg 44tk; 50mg+150mg+50mg 98tk; 50mg+150mg+50mg 104tk

Estónsko - estónčina - Ravimiamet

bayer animal health gmbh - prasikvanteel+febanteel+püranteel - tablett - 175mg+525mg+174,6mg 24tk; 175mg+525mg+174,6mg 4tk

Estónsko - estónčina - Ravimiamet

bayer animal health gmbh - prasikvanteel+febanteel+püranteel - tablett - 50mg+150mg+144mg 2tk; 50mg+150mg+144mg 24tk

Európska únia - estónčina - EMA (European Medicines Agency)

aventis pharma s.a. - telitromütsiin - community-acquired infections; pharyngitis; bronchitis, chronic; pneumonia; tonsillitis; sinusitis - antibacterials süsteemseks kasutamiseks, - levviax'i määramisel tuleks kaaluda antibakteriaalsete ainete asjakohase kasutamise ametlikke juhiseid ja resistentsuse kohalikku levikut (vt ka lõiked 4. 4 ja 5. levviax on näidustatud ravi järgmiste infektsioonide korral:patsientidel, 18 aastat ja vanemad:-Ühenduse-omandatud kopsupõletik, kerge või mõõdukas (vt lõik 4. - kui ravivad infektsioonid, mis on põhjustatud teadaolevalt või arvatavasti beeta-lactam ja/või makroliid resistentsete tüvede (vastavalt ajalugu patsientidel või riiklike ja/või piirkondlike resistentsus andmed) hõlmatud antibakteriaalne spekter telithromycin (vt lõigud 4. 4 ja 5. 1):- Äge ägenemine krooniline bronhiit,- Äge sinusitisin patsientide 12-aastased ja vanemad:- tonsilliit/; farüngiit; põhjustatud streptococcus pyogenes, alternatiivina, kui beeta lactam antibiootikumid ei ole asjakohane riikides/piirkondades, kus suur levimus makroliid vastupidavad s. pyogenes, kui see vahendab ermtr või mefa (vt. lõigud 4. 4 ja 5.

Európska únia - estónčina - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastilised ained - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Európska únia - estónčina - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. kasutamist see vaktsiin peaks olema kooskõlas ametlike soovitustega.

Európska únia - estónčina - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, soole põletikuvastased / antiinfective ained - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

Európska únia - estónčina - EMA (European Medicines Agency)

pfizer europe ma eeig  - palbociclib - rinnanäärmed - antineoplastilised ained - ibrance on näidustatud ravi hormooni retseptori (hr) positiivne, inimese epidermaalse kasvufaktori retseptor 2 (her2) negatiivne lokaalselt kaugelearenenud või metastaatilise rinnavähi:kombinatsioonis aromataasi inhibiitor;koos fulvestrant naistel, kes on saanud enne endokriinse ravi. pre - või perimenopausal naised, endokriinse ravi tuleks koos luteiniseeriva hormooni vabastav hormoon (lhrh) agonist.